GHRP-6 (5 mg vial)

Protocol Overview

Concise summary of the regimen.

Dosing & Reconstitution

Frequency: Inject three times daily subcutaneously, spaced at least 4 hours apart (morning, midday, bedtime). GHRP-6 has a short half-life of approximately 2.5 hours, making multiple daily injections more effective than once-daily dosing for sustained GH elevation. Each injection should be administered on an empty stomach (2 to 3 hours after meals, 30 minutes before eating) to maximize GH release.

Reconstitution Steps

1. Draw 3.0 mL bacteriostatic water with a sterile syringe.
2. Inject slowly down the vial wall to avoid foaming; do not shake.
3. Gently swirl or roll the vial until the powder is completely dissolved.
4. Label with date and concentration; refrigerate at 2 to 8 °C, protected from light.
5. Use within 7 days of reconstitution for optimal potency. At 1.67 mg/mL, 1 unit = 0.01 mL » 16.7 mcg on a U-100 insulin syringe.

Storage Instructions

Proper storage preserves peptide quality.

• Lyophilized: store at -20 °C in dry, dark conditions with desiccant if available.
• Reconstituted: refrigerate at 2 to 8 °C; use within 7 days.
• Avoid freeze-thaw cycles: do not refreeze reconstituted solution; prepare aliquots if extended storage is

needed.

• Allow vials to reach room temperature before opening to minimize condensation.

Supplies Needed

Plan based on a 12-week protocol with three-times-daily injections and gradual titration.

Peptide Vials (GHRP-6, 5 mg each):

• 12 weeks: ~13 vials (based on gradual titration to 300 mcg x 3 daily).

Insulin Syringes (U-100):

• Per week: 21 syringes (3/day x 7 days).
• 12 weeks: 252 syringes (3 x 100-count boxes).

Bacteriostatic Water (10 mL bottles):

• 12 weeks (13 vials): 39 mL (4 bottles).

Alcohol Swabs:

• Per week: 42 swabs (2 per injection x 3 daily x 7 days).
• 12 weeks: 504 swabs (6 x 100-count boxes).

Important Notes

Practical considerations for consistency and safety.

• Use new sterile insulin syringes for each injection; dispose in a sharps container.
• Rotate injection sites systematically (abdomen, thighs, upper arms) to reduce lipohypertrophy and local

irritation.

• Inject slowly and wait a few seconds before withdrawing the needle.
• GHRP-6 may increase appetite in some users due to its ghrelin-mimicking properties.
• Document daily doses, timing, and sites to maintain consistency throughout the cycle.

How This Works

GHRP-6 functions as a synthetic ghrelin mimetic by binding to the growth hormone secretagogue receptor (GHS-R1a) in the pituitary gland and hypothalamus. This activation triggers acute, pulsatile growth hormone release from somatotroph cells while simultaneously reducing somatostatin's inhibitory brake on GH secretion. Unlike continuous GH administration, GHRP-6 maintains physiological feedback controls: as GH and IGF-1 levels rise, endogenous somatostatin increases to prevent excessive elevation, keeping GH pulses within normal physiologic ranges. Beyond its endocrine effects, GHRP-6 exhibits cytoprotective properties through interactions with the CD36 receptor on immune and muscle cells. This secondary pathway activates cell-survival signaling cascades (such as PI3K/Akt) that help protect tissues from oxidative stress and inflammation, explaining many of GHRP-6's observed tissue-protective benefits in preclinical models including cardioprotection, neuroprotection, and anti-fibrotic effects.

Benefits & Side Effects

Observations from clinical and preclinical literature.

• Muscle Growth & Fat Loss: Elevated GH and IGF-1 levels support increased lean body mass and

reduced fat mass over time.

• Enhanced Recovery: Improved sleep architecture (increased slow-wave sleep) and faster tissue repair.
• Appetite Stimulation: May increase hunger due to ghrelin receptor activation, potentially beneficial for

weight gain goals.

• Tissue Protection: Preclinical studies show cytoprotective effects including reduced scar formation,

cardioprotection, and neuroprotection.

• Joint & Connective Tissue Health: May support collagen synthesis and connective tissue repair

through elevated IGF-1.

• Transient mild increases in cortisol and ACTH (typically not clinically significant).
• Increased appetite and potential water retention.
• Occasional injection-site reactions (redness, itching, mild swelling).
• Possible transient dizziness or flushed feeling immediately after injection due to rapid GH spike.
• Generally well-tolerated in human trials at research doses with no major safety concerns reported.

Lifestyle Factors

Complementary strategies for best outcomes.

• Nutrition: maintain adequate protein intake (1.6 to 2.2 g/kg body weight) to support anabolic processes.

Time carbohydrate and fat intake away from injections to maximize GH release.

• Training: combine resistance training with moderate cardiovascular activity to leverage elevated

GH/IGF-1.

• Sleep: prioritize 7 to 9 hours of quality sleep; GHRP-6's effects on sleep architecture may enhance

recovery.

• Hydration: maintain proper hydration to support metabolic processes and minimize water retention.
• Stress management: chronic stress can interfere with GH secretion.

Injection Technique

General subcutaneous guidance from clinical best-practice resources.

1. Clean the vial stopper and skin with alcohol; allow to dry.
2. Pinch a skinfold; insert the needle at 45 to 90 degrees into subcutaneous tissue.
3. Do not aspirate for subcutaneous injections; inject slowly and steadily.
4. Wait 5 to 10 seconds before withdrawing; dispose of syringe in sharps container.
5. Rotate sites systematically (abdomen, thighs, upper arms) to avoid lipohypertrophy.

References

Source citations for further reading.

1. Growth hormone-releasing peptides: comprehensive review of GHRP mechanisms (European Journal of Endocrinology, 1997).
2. Synthetic GHRPs: historical appraisal of cytoprotective effects and mechanisms (Clinical Medicine Insights: Cardiology, 2017).
3. Pharmacokinetic study of GHRP-6 in healthy male volunteers (European Journal of Pharmaceutical Sciences, 2013).
4. GHRP-6 prevents cutaneous hypertrophic scarring: proteome study (International Wound Journal, 2018).